Agenus shared a post on LinkedIn:
“Yesterday at AACRIO25, we presented new translational insights demonstrating the strong immune activation driven by BOT/BAL in combination with chemotherapy and MiNK Therapeutics’ allo-iNKTs in refractory gastric cancer.
Read more about the data.”